Functional central nicotinic acetylcholine receptor antagonism by systemic administration of tinuvin 770 (BTMPS)

Current Alzheimer Research

Volumn 2, Issue 2, 2005, Pages 141-147

  Graham, John H ^a   Papke, Roger L ^b   Buccafusco, Jerry J ^c,d  

^a King College   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Antinociception; Autonomic ganglia; Blood pressure; DMPP; Motor activity; Nicotine; Nicotinic receptor; Tinuvin 770

Indexed keywords

1,1 DIMETHYL 4 PHENYLPIPERAZINIUM; DROMETRIZOLE; MECAMYLAMINE; NICOTINE; NICOTINIC RECEPTOR; PIPERIDINE DERIVATIVE; TINUVIN 770; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANTINOCICEPTION; CENTRAL NERVOUS SYSTEM; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG SOLUBILITY; HOT PLATE TEST; LOCOMOTION; MALE; NONHUMAN; PERIPHERAL NERVOUS SYSTEM; PRESSOR RESPONSE; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING;

ANIMALS; DECANOIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MOTOR ACTIVITY; NICOTINIC ANTAGONISTS; PIPERIDINES; RATS; RATS, WISTAR; RECEPTORS, NICOTINIC;

EID: 20844434042     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/1567205053585747     Document Type: Conference Paper

References (38)

1. Terry AV Jr. and Buccafusco JJ. The Cholinergic Hypothesis of Alzheimer's Disease: Recent Challenges and Their Implications for Novel Drug Development. J Pharmacol Exp Ther 306: 821-827 (2003).
2. Buccafusco JJ. The cholinergic hypothesis - past and present. In 'Cognitive Enhancing Drugs' (Ed: Buccafusco JJ), Birkhäuser, Basel, p. 1-10 (2004).
3. Nordberg A. Nicotinic receptor abnormalities of Alzheimer's disease: therapeutic implications. Biological Psychiatry 49: 200-210 (2001).
4. Perry EK, Martin-Ruiz CM and Court JA. Nicotinic receptor subtypes in human brain related to aging and dementia. Alcohol 24: 63-68 (2001).
5. Patel S and Tariot PN. Pharmacologic models of Alzheimer's disease. Psychiatric Clinics of North America 14: 287-308 (1991).
6. Elrod K and Buccafusco, JJ. Correlation of the amnestic effects of nicotinic antagonists with inhibition of regional brain acetylcholine synthesis in rats. J Pharmacol Exp Ther 258: 403-409 (1991).
7. Levin ED and Simon BB. Nicotinic acetylcholine involvement in cognitive function in animals Psychopharmacology 138: 217-230 (1998).
8. Young JM, Shytle RD, Sanberg PR and George TP. Mecamylamine: new therapeutic uses and toxicity/risk profile. Clin Therap 23: 532-565 (2001).
9. Papke RL, Craig GA and Heinemann SF. Inhibition of nicotinic acetlylcholine receptors by bis (2,2,6,6-tetramethyl-4-piperidinyl) sebacate (Tinuvin 770), an additive to medical plasitics. J Pharmacol Exp Ther 268: 718-726 (1994).
10. Nedergaard OA and Schrold J. The mechanism of action of nicotine on vascular adrenergic neuroeffector transmission. Eur J Pharmacol 42: 315-329 (1977).
11. Taylor P. Agents acting at the neuromuscular junction and autonomic ganglia. In 'Goodman and Gilman's The Pharmacological Basis of Therapeutics' (Eds: Hardman, JG, Limbird LE and Gilman AG), McGraw Hill, New York, p. 193-214 (2001).
12. Buccafusco JJ, Graham JH and Aronstam RS. Behavioral effects of toxic doses of soman, an organophosphate cholinesterase inhibitor, in the rat: Protection afforded by clonidine. Pharmacol Biochem Behav 29: 309-313 (1989).
13. Lukas RJ, Changeux J-P, le Novère N, Albuquerque EX, Balfour DJK, Berg DK, Bertrand D, Chiappinelli VA, Clarke PBS, Collins AC, Dani JA, Grady SR, Kellar KJ, Lindstrom JM, Marks MJ, Quik M, Taylor PW and Wonnacott S. International Union of Pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits. Pharmacol Rev 51: 397-401 (1999).
14. Buccafusco JJ. Neuronal nicotinic receptor subtypes: defining therapeutic targets. Mol Interventions 4: 285-295 (2004).
15. Buccafusco JJ, Finberg JPM and Spector S. Mechanism of the antihypertensive action of clonidine on the pressor response to physostigmine. J Pharmacol Exp Ther 212: 58-63 (1980).
16. Doraiswamy PM. Non-cholinergic strategies for treating and preventing Alzheimer's disease. CNS Drugs 16: 811-24 (2002).
17. 3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex. Eur J Pharmacol 166: 589-590 (1989).
18. el-Bizri H and Clarke PB. Regulation of nicotinic receptors in rat brain following quasi-irreversible nicotinic blockade by chlorisondamine and chronic treatment with nicotine. Br J Pharmacol 113: 917-925 (1994).
19. Bevins RA and Besheer J. Individual differences in rat locomotor activity are diminished by nicotine through stimulation of central nicotinic acetylcholine receptors. Physiol Behav 72: 237-244 (2001).
20. Buccafusco, JJ, Jackson WJ, Jonnala RR and Terry Jr AV. Differential improvement in memory-related task performance to nicotine by aged male and female rhesus monkeys. Behav Pharmacol 10: 681-690 (1999).
21. Levin ED. Nicotinic receptor subtypes and cognitive function. J Neurobiol 53: 633-640 (2002).
22. Briggs CA and McKenna DG. Activation and inhibition of the human alpha7 nicotinic acetylcholine receptor by agonists. Neuropharmacology. 37: 1095-1102 (1998).
23. Fenster CP, Whitworth TL, Sheffield EB, Quick MW and Lester RA. Upregulation of surface alpha4beta2 nicotinic receptors is initiated by receptor desensitization after chronic exposure to nicotine. J Neurosci 19:4804-4814 (1999).
24. Damaj MI, Meyer EM and Martin BR. The antinociceptive effects of alpha7 nicotinic agonists in an acute pain model. Neuropharmacology 39: 2785-2791 (2000).
25. Tassonyi E, Charpantier E, Muller D, Dumont L and Bertrand D. The role of nicotinic acetylcholine receptors in the mechanisms of anesthesia. Brain Res Bull 57: 133-150 (2002).
26. Decker MW, Rueter LE and Bitner RS. Nicotinic acetylcholine receptor agonists: a potential new class of analgesics. Current Topics Med Chem 4: 369-384 (2004).
27. Iwamoto ET. Characterization of the antinociception induced by nicotine in the pedunculopontine tegmental nucleus and the nucleus raphe magnus. J Pharmacol Exp Ther 257: 120-133 (1991).
28. Bannon AW, Decker MW, Holladay MW, Curzon P, Donnelly-Roberts D, Puttfarcken PS, Bitner RS, Diaz A, Dickenson AH, Porsolt RD, Williams M and Arneric SP. Broad-spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors. Science 279: 77-81 (1998).
29. Cridland RA and Henry JL. Facilitation of the tail-flick reflex by noxious cutaneous stimulation in the rat: antagonism by a substance P analogue. Brain Res 462: 15-21 (1988).
30. Yaksh TL. Pharmacology and mechanisms of opioid analgesic activity. Acta Anaesthesiol Scand 41: 94-111 (1997).
31. 2+-channel blocker. Proc NY Acad Sci 90:9523-9527 (1993).
32. Elrod K, Buccafusco JJ and Jackson WJ. Nicotine enhances delayed matching-to-sample performance by primates. Life Sci 43: 277-287 (1988).
33. Levin ED, Rose JE, McGurk SR and Butcher LL. Characterization of the cognitive effects of combined muscarinic and nicotinic blockade. Behav Neural Biol 53: 103-112 (1990).
34. Decker MW and Majchrzak MJ. Effects of systemic and intracerebroventricular administration of mecamylamine, a nicotinic cholinergic antagonist, on spatial memory in rats. Psychopharmacology 107:530-534 (1992).
35. Newhouse PA, Potter A, Corwin J and Lenox R. Age-related effects of the nicotinic antagonist mecamylamine on cognition and behavior. Neuropsychopharmacology 10: 93-107 (1994).
36. Levin ED, Kaplan S and Boardman A. Acute nicotine intentions with nicotinic and muscarinic antagonists: working and reference memory effects in the 16-arm radial maze. Behav Pharmacol 8: 236-242 (1997).
37. Little JT, Johnson DN, Minichiello M, Weingartner H and Sunderland T. Combined nicotinic and muscarinic blockade in elderly normal volunteers: cognitive, behavioral, and physiologic responses. Neuropsychopharmacology. 19: 60-69 (1998).
38. Brown RW, Beale KS and Jay Frye GD. Mecamylamine blocks enhancement of reference memory but not working memory produced by post-training injection of nicotine in rats tested on the radial arm maze. Behav Brain Res 134: 259-265 (2002).